Fingerprint
Dive into the research topics of 'Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
the CONTROL Study Investigators
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Institute of Clinical and Translational Sciences
- Siteman Cancer Center
- Section of Molecular Oncology & Developmental Therapeutics
- DBBS - Molecular Cell Biology
- DBBS - Biochemistry, Biophysics, and Structural Biology
- DBBS - Cancer Biology
Research output: Contribution to journal › Article › peer-review
49
Scopus
citations